EMA Authorised: Oxlumo (Lumasiran sodium) — Alnylam Netherlands B.V.

View source ↗

Summary

The European Medicines Agency has authorised Oxlumo (lumasiran sodium) for primary hyperoxaluria, an orphan disease, with marketing authorization held by Alnyla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria

Drugs mentioned

• Oxlumo (lumasiran)

Snippet

Status: Authorised. Therapeutic area: Hyperoxaluria, Primary. MAH: Alnylam Netherlands B.V.. Decision date: 04/08/2025. Orphan medicine